Welcome to our dedicated page for ProtoKinetix SEC filings (Ticker: PKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ProtoKinetix, Incorporated filings document the regulatory record for a Nevada clinical-stage biomedical company developing AAGP®/PKX-001 applications. Recent Form 8-K and 8-K/A reports cover Regulation FD stockholder updates, leadership and board changes, and amendments to previously furnished company communications.
Proxy and consent-solicitation materials describe stockholder approval of an amendment to the articles of incorporation increasing authorized common shares. The filing record also includes Form 12b-25 notices related to annual-report timing and disclosures on the company’s common-stock authorization, governance actions, and public-company reporting status.
ProtoKinetix, Inc. director Jason G. Lamp reports ownership of 6,496,878 shares of the company’s Common Stock. The position is reported as directly held as of 2026-06-17, with no accompanying purchase or sale transactions disclosed.
ProtoKinetix, Inc. director and President Keith R. Brunt filed an initial ownership report showing his equity position in the company. He reports indirect ownership of 1,030,000 shares of Common Stock held by NBBM Inc. and direct ownership of 2,042,572 shares of Common Stock.
Brunt also reports stock options over 2,750,000 shares of Common Stock with an exercise price of $0.01 per share, expiring on December 6, 2030, issued under the company’s 2019 Equity Incentive Plan. This filing records existing holdings rather than reporting new buy or sell transactions.
ProtoKinetix, Inc. director Michael Winston Jones filed an initial ownership report on Form 3. The filing shows he directly holds 6,400,000 shares of Common Stock after the reported date. This is a disclosure of existing holdings, not a report of a new stock purchase or sale.
ProtoKinetix, Inc. reported several corporate updates. Longtime director Edward McDonough resigned from the board, stating his decision was not due to any disagreement with the company. The board then appointed Michael Jones and Jason Lamp as new directors, and named translational scientist Dr. Keith Brunt as both a director and president.
The company formed a wholly owned subsidiary, SightPath Biotech LLC, to develop its PKX-001 synthetic glycopeptide for dry-eye disease and other ocular conditions. Two independent analyses in 2021 and 2025 estimated the present value of related patents and development work at approximately $253 million, reflecting factors such as novel IP, market size, and competitive position.
ProtoKinetix disclosed that it filed Form 12b-25 notices for delayed filing of its 2025 annual report and first-quarter 2026 quarterly report and is working on completing these filings. The board also approved repricing options covering 61,190,000 shares and warrants for 6,000,000 shares from a $0.028 to $0.01 exercise price and extended their expiration dates by two years.
Protokinetix, Inc. submitted a Form 12b-25 notifying the SEC that it could not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 because of delays completing financial statements and management's discussion and analysis.
The company states the independent registered public accounting firm requires additional review time and that it anticipates filing the Quarterly Report no later than the fifteenth calendar day following the prescribed due date. The notification is signed by CEO Michael Guzzetta dated May 15, 2026.
Protokinetix, Inc. submitted a Form 12b-25 notifying the SEC it could not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 due to delays finalizing financial statements and MD&A. The registrant states it expects to file the Annual Report no later than the fifteenth calendar day following the prescribed due date for smaller reporting companies (original filing date March 31, 2026). The notification was executed by Michael Guzzetta on March 31, 2026.
ProtoKinetix, Incorporated furnished a company update to its stockholders. The update was distributed by the company and is included as Exhibit 99.1 to this report, where the full text can be read.
The information is provided under a Regulation FD disclosure, meaning it is intended to share information with all investors at the same time. The company specifies that this material is being furnished rather than filed, so it is not automatically incorporated into other securities law filings.
ProtoKinetix, Incorporated (PKTX) filed an amended Form 8-K to update a prior current report. The Amendment corrects the Company’s contact telephone number and attaches a revised version of a press release that was posted on the Company’s website on November 17, 2025.
The updated press release is furnished as Exhibit 99.1 under Regulation FD Disclosure and is not treated as filed for liability purposes or incorporated by reference into other securities law filings. No financial results, business strategy, or transactional details are changed by this Amendment.
ProtoKinetix, Inc. announced a major leadership change following the unexpected death of its long-time President and Chief Executive Officer, Clarence E. Smith, in an accident on November 13, 2025. Smith had led the company’s management and served on its Board of Directors for many years.
Under the company’s bylaws, sole remaining director Ed McDonough appointed Michael Guzzetta as Chairman of the Board, President, and Chief Executive Officer on November 16, 2025. Guzzetta will also continue in his existing roles as Chief Financial Officer, Secretary, and Treasurer, resulting in one individual holding all principal executive and financial positions. His compensation under his existing employment agreement has not been changed. The company furnished a press release on November 17, 2025 to formally announce these leadership changes.
ProtoKinetix (PKTX) filed its Q3 2025 10‑Q, reporting a net loss of $84,906 for the quarter and $273,663 for the nine months. The company ended the period with $607 in cash, total assets of $477,623, liabilities of $227,196, and stockholders’ equity of $250,427.
To fund operations, ProtoKinetix completed small private placements in 2025: 17,700,000 units for $172,500 cash plus $4,500 in services, and 500,000 shares for $5,000. Between July 25 and September 25, it issued 1,000,000 shares for $10,000. Options outstanding were 94,790,000 and warrants outstanding were 23,700,000 as of September 30, 2025. As of November 13, 2025, 391,580,152 common shares were outstanding.
Management disclosed substantial doubt about the company’s ability to continue as a going concern and stated disclosure controls and procedures were not effective as of September 30, 2025. Stockholders approved an amendment increasing authorized common shares from 500,000,000 to 600,000,000.